Logo image of REGN

REGENERON PHARMACEUTICALS (REGN) Stock Fundamental Analysis

NASDAQ:REGN - US75886F1075 - Common Stock

579.8 USD
-9.68 (-1.64%)
Last: 8/25/2025, 10:48:44 AM
Fundamental Rating

7

Overall REGN gets a fundamental rating of 7 out of 10. We evaluated REGN against 547 industry peers in the Biotechnology industry. Both the health and profitability get an excellent rating, making REGN a very profitable company, without any liquidiy or solvency issues. REGN scores decently on growth, while it is valued quite cheap. This could make an interesting combination. This makes REGN very considerable for value investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

8

1. Profitability

1.1 Basic Checks

In the past year REGN was profitable.
REGN had a positive operating cash flow in the past year.
REGN had positive earnings in each of the past 5 years.
Each year in the past 5 years REGN had a positive operating cash flow.
REGN Yearly Net Income VS EBIT VS OCF VS FCFREGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

1.2 Ratios

REGN's Return On Assets of 11.67% is amongst the best of the industry. REGN outperforms 94.52% of its industry peers.
REGN has a Return On Equity of 14.89%. This is amongst the best in the industry. REGN outperforms 94.33% of its industry peers.
Looking at the Return On Invested Capital, with a value of 9.28%, REGN belongs to the top of the industry, outperforming 93.78% of the companies in the same industry.
The Average Return On Invested Capital over the past 3 years for REGN is below the industry average of 16.04%.
Industry RankSector Rank
ROA 11.67%
ROE 14.89%
ROIC 9.28%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
REGN Yearly ROA, ROE, ROICREGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30 40

1.3 Margins

REGN has a Profit Margin of 31.37%. This is amongst the best in the industry. REGN outperforms 96.34% of its industry peers.
REGN's Profit Margin has improved in the last couple of years.
REGN has a better Operating Margin (28.56%) than 96.53% of its industry peers.
REGN's Operating Margin has been stable in the last couple of years.
REGN has a Gross Margin of 86.46%. This is amongst the best in the industry. REGN outperforms 89.21% of its industry peers.
REGN's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 28.56%
PM (TTM) 31.37%
GM 86.46%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
REGN Yearly Profit, Operating, Gross MarginsREGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20 40 60 80

More info and screens

8

2. Health

2.1 Basic Checks

REGN has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
Compared to 1 year ago, REGN has about the same amount of shares outstanding.
Compared to 5 years ago, REGN has less shares outstanding
The debt/assets ratio for REGN has been reduced compared to a year ago.
REGN Yearly Shares OutstandingREGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
REGN Yearly Total Debt VS Total AssetsREGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10B 20B 30B

2.2 Solvency

REGN has an Altman-Z score of 6.90. This indicates that REGN is financially healthy and has little risk of bankruptcy at the moment.
REGN has a Altman-Z score of 6.90. This is amongst the best in the industry. REGN outperforms 80.62% of its industry peers.
REGN has a debt to FCF ratio of 0.76. This is a very positive value and a sign of high solvency as it would only need 0.76 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.76, REGN belongs to the top of the industry, outperforming 95.61% of the companies in the same industry.
A Debt/Equity ratio of 0.09 indicates that REGN is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.09, REGN is doing worse than 63.62% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for REGN, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.76
Altman-Z 6.9
ROIC/WACC0.97
WACC9.57%
REGN Yearly LT Debt VS Equity VS FCFREGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B 20B 25B

2.3 Liquidity

REGN has a Current Ratio of 4.60. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of REGN (4.60) is comparable to the rest of the industry.
REGN has a Quick Ratio of 3.93. This indicates that REGN is financially healthy and has no problem in meeting its short term obligations.
REGN has a Quick ratio (3.93) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 4.6
Quick Ratio 3.93
REGN Yearly Current Assets VS Current LiabilitesREGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5B 10B 15B

More info and screens

4

3. Growth

3.1 Past

REGN shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 2.42%.
REGN shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 13.12% yearly.
REGN shows a small growth in Revenue. In the last year, the Revenue has grown by 5.38%.
The Revenue has been growing by 12.55% on average over the past years. This is quite good.
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%

3.2 Future

Based on estimates for the next years, REGN will show a small growth in Earnings Per Share. The EPS will grow by 5.55% on average per year.
REGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 5.04% yearly.
EPS Next Y-12.44%
EPS Next 2Y-3.76%
EPS Next 3Y2.99%
EPS Next 5Y5.55%
Revenue Next Year-1.9%
Revenue Next 2Y1.48%
Revenue Next 3Y4.14%
Revenue Next 5Y5.04%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
REGN Yearly Revenue VS EstimatesREGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 5B 10B 15B
REGN Yearly EPS VS EstimatesREGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 20 40 60

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 12.70, which indicates a correct valuation of REGN.
Compared to the rest of the industry, the Price/Earnings ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 96.16% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 27.24, REGN is valued rather cheaply.
With a Price/Forward Earnings ratio of 13.72, REGN is valued correctly.
Based on the Price/Forward Earnings ratio, REGN is valued cheaply inside the industry as 95.43% of the companies are valued more expensively.
REGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 22.81.
Industry RankSector Rank
PE 12.7
Fwd PE 13.72
REGN Price Earnings VS Forward Price EarningsREGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of REGN indicates a rather cheap valuation: REGN is cheaper than 96.34% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, REGN is valued cheaper than 95.25% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.28
EV/EBITDA 11.43
REGN Per share dataREGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 50 100 150 200 250

4.3 Compensation for Growth

REGN has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.97
EPS Next 2Y-3.76%
EPS Next 3Y2.99%

More info and screens

2

5. Dividend

5.1 Amount

With a yearly dividend of 0.59%, REGN is not a good candidate for dividend investing.
Compared to an average industry Dividend Yield of 96.44, REGN pays a better dividend. On top of this REGN pays more dividend than 97.99% of the companies listed in the same industry.
Compared to an average S&P500 Dividend Yield of 2.34, REGN's dividend is way lower than the S&P500 average.
Industry RankSector Rank
Dividend Yield 0.59%

5.2 History

REGN is new to the dividend game and has less than 3 years of track record.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years0
REGN Yearly Dividends per shareREGN Yearly Dividends per shareYearly Dividends per share 2025 0.5 1 1.5 2 2.5

5.3 Sustainability

DPN/A
EPS Next 2Y-3.76%
EPS Next 3Y2.99%
REGN Yearly Income VS Free CF VS DividendREGN Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B 8B

More info and screens

REGENERON PHARMACEUTICALS

NASDAQ:REGN (8/25/2025, 10:48:44 AM)

579.8

-9.68 (-1.64%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-01 2025-08-01/bmo
Earnings (Next)10-29 2025-10-29/bmo
Inst Owners91.91%
Inst Owner Change-5.4%
Ins Owners1.86%
Ins Owner Change0%
Market Cap61.45B
Analysts80
Price Target745.42 (28.57%)
Short Float %2.2%
Short Ratio2.24
Dividend
Industry RankSector Rank
Dividend Yield 0.59%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-Date08-18 2025-08-18 (0.88)
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)20.56%
Min EPS beat(2)-8.66%
Max EPS beat(2)49.77%
EPS beat(4)3
Avg EPS beat(4)12.63%
Min EPS beat(4)-8.66%
Max EPS beat(4)49.77%
EPS beat(8)6
Avg EPS beat(8)8.06%
EPS beat(12)10
Avg EPS beat(12)9%
EPS beat(16)13
Avg EPS beat(16)9.97%
Revenue beat(2)1
Avg Revenue beat(2)0.2%
Min Revenue beat(2)-9.31%
Max Revenue beat(2)9.72%
Revenue beat(4)1
Avg Revenue beat(4)-0.28%
Min Revenue beat(4)-9.31%
Max Revenue beat(4)9.72%
Revenue beat(8)4
Avg Revenue beat(8)0.25%
Revenue beat(12)8
Avg Revenue beat(12)1.29%
Revenue beat(16)12
Avg Revenue beat(16)3.14%
PT rev (1m)-0.82%
PT rev (3m)-9.57%
EPS NQ rev (1m)4.73%
EPS NQ rev (3m)-15.21%
EPS NY rev (1m)10.71%
EPS NY rev (3m)9.87%
Revenue NQ rev (1m)4.15%
Revenue NQ rev (3m)-4.24%
Revenue NY rev (1m)3.78%
Revenue NY rev (3m)3.68%
Valuation
Industry RankSector Rank
PE 12.7
Fwd PE 13.72
P/S 4.32
P/FCF 17.28
P/OCF 12.96
P/B 2.05
P/tB 2.15
EV/EBITDA 11.43
EPS(TTM)45.64
EY7.87%
EPS(NY)42.27
Fwd EY7.29%
FCF(TTM)33.55
FCFY5.79%
OCF(TTM)44.75
OCFY7.72%
SpS134.11
BVpS282.47
TBVpS269.72
PEG (NY)N/A
PEG (5Y)0.97
Profitability
Industry RankSector Rank
ROA 11.67%
ROE 14.89%
ROCE 11.75%
ROIC 9.28%
ROICexc 11.84%
ROICexgc 12.46%
OM 28.56%
PM (TTM) 31.37%
GM 86.46%
FCFM 25.02%
ROA(3y)12.83%
ROA(5y)18.14%
ROE(3y)16.47%
ROE(5y)24.86%
ROIC(3y)12.18%
ROIC(5y)17.79%
ROICexc(3y)40.56%
ROICexc(5y)38.47%
ROICexgc(3y)47.83%
ROICexgc(5y)42.84%
ROCE(3y)15.42%
ROCE(5y)22.52%
ROICexcg growth 3Y-3.25%
ROICexcg growth 5Y17.1%
ROICexc growth 3Y-7.38%
ROICexc growth 5Y14.08%
OM growth 3Y-18.89%
OM growth 5Y1.11%
PM growth 3Y-14.8%
PM growth 5Y2.92%
GM growth 3Y0.85%
GM growth 5Y-0.68%
F-Score5
Asset Turnover0.37
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF 0.76
Debt/EBITDA 0.59
Cap/Depr 232.74%
Cap/Sales 8.35%
Interest Coverage 250
Cash Conversion 103.81%
Profit Quality 79.76%
Current Ratio 4.6
Quick Ratio 3.93
Altman-Z 6.9
F-Score5
WACC9.57%
ROIC/WACC0.97
Cap/Depr(3y)292.07%
Cap/Depr(5y)265.92%
Cap/Sales(3y)8.85%
Cap/Sales(5y)7.44%
Profit Quality(3y)83.77%
Profit Quality(5y)77.84%
High Growth Momentum
Growth
EPS 1Y (TTM)2.42%
EPS 3Y-13.85%
EPS 5Y13.12%
EPS Q2Q%11.51%
EPS Next Y-12.44%
EPS Next 2Y-3.76%
EPS Next 3Y2.99%
EPS Next 5Y5.55%
Revenue 1Y (TTM)5.38%
Revenue growth 3Y-4.04%
Revenue growth 5Y12.55%
Sales Q2Q%3.62%
Revenue Next Year-1.9%
Revenue Next 2Y1.48%
Revenue Next 3Y4.14%
Revenue Next 5Y5.04%
EBIT growth 1Y-2.61%
EBIT growth 3Y-22.17%
EBIT growth 5Y13.8%
EBIT Next Year-14.3%
EBIT Next 3Y4.69%
EBIT Next 5Y5.9%
FCF growth 1Y18.37%
FCF growth 3Y-18.47%
FCF growth 5Y12.09%
OCF growth 1Y0.1%
OCF growth 3Y-14.54%
OCF growth 5Y12.71%